Treatment with a combination of the natural food components curcumin and genistein can lead to a therapeutic level of restoration of the CFTR protein channel activity in patients with a class III, S1251N gating mutation.. Measurements in vitro can…
ID
Bron
Verkorte titel
Aandoening
Cystic Fibrosis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Sweat chloride concentration (SCC) before and after treatment with curcumin and genistein.
Achtergrond van het onderzoek
We hypothesized that treatment with a combination of the natural food components curcumin and genistein can lead to a therapeutic level of restoration of the CFTR protein channel activity in patients with a class III, S1251N gating mutation.
Measurements in vitro (in organoids) can predict the individual treatment efficacy of curcumin and genistein. Primary objective is to investigate the therapeutic potential of the natural food components curcumin and genistein in Dutch CF patients carrying the S1251N gating mutation.
A secondary objective is to evaluate the correlations between individual curcumin+genistein induced CFTR function in vitro and the in vivo treatment effect. Another secondary objective is to evaluate the CFTR stimulating ability of the concentration of curcumin+genistein in the patient’s blood samples, examined by in vitro testing.Children, adolescents and adults with Cystic Fibrosis who are 6 years or older and have a compound/S1251N class III gating mutation will receive curcumin and genistein in a dosage that is based on their weight during 8 weeks.. Main study parameter will be sweat chloride concentrationbefore and after receiving curcumin+genistein.
Doel van het onderzoek
Treatment with a combination of the natural food components curcumin and genistein can lead to a therapeutic level of restoration of the CFTR protein channel activity in patients with a class III, S1251N gating mutation.. Measurements in vitro can predict the individual treatment efficacy of curcumin and genistein.
Onderzoeksopzet
Before and after the use of curcumin+genistein
Onderzoeksproduct en/of interventie
All patients will use the feeding supplements curcumin and genistein in a dosage that is based on their weight, during the first 8 weeks.
Publiek
Huispostnummer KH 01.419.0
Postbus 85090
S. Michel
Utrecht 3508 AB
The Netherlands
+31 (0)88 75 537 25
s.michel-2@umcutrecht.nl
Wetenschappelijk
Huispostnummer KH 01.419.0
Postbus 85090
S. Michel
Utrecht 3508 AB
The Netherlands
+31 (0)88 75 537 25
s.michel-2@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• CFTR genotype compound/ S1251N
• Had a rectal biopsy to produce an organoid
• Male and female patients, aged 6 years or older on the date of informed consent or, where appropriate, date of assent
• Signed informed consent form (IC), and where appropriate, signed assent form
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Severe acute exacerbation or pulmonary infection during last four weeks (needing intravenous treatment and/or systemic corticosteroids);
• Use of curcumin and or genistein at start or within four weeks prior to start of the study.
• Participation in another drug-investigating clinical study at the start or within four weeks prior to the start;
• Known cholelithiasis;
• Inability to follow instructions of the investigator.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4371 |
| NTR-old | NTR4585 |
| CCMO | NL48122.041.14 |
| OMON | NL-OMON40933 |